Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Advaxis, Inc.
Advaxis Develops Innovative Approach in Cancer Mechanism Targeting
June 17th, 2009
Advaxis Incorporated (OTCBB:ADXS) has developed an innovative approach in targeting cancer that enables a single bioengineered Listeria monocytogenes (Lm) bacterium to simultaneously secrete two different antigen-adjuvant fusion proteins. Under a patent-pending filed on May 26, 2009 with the US Patent and Trademark Office, this advance would allow a vaccine, targeted against a cancer, to stimulate a therapeutic immune attack against two different therapeutic targets, whereby there is a tumor specific antigen, and an anti-angiogenic target designed to reduce the production of blood vessels necessary to allow cancer growth. As an example, in the treatment of breast...
Source: Vaccine Weekly (2009-06-17)
|
